Cardiology Highlight Reel 2015 – Lipids
Details & Video
Learn how to select the right patient for a PCSK9 inhibitor!
Join Dr. Kausik Ray in conversation discussing where LDL-C targets may be going, the association between statins and new onset diabetes, and the introduction of new lipid-lowering drugs.
The Cardiology Highlight Reel 2015 series engages world-renowned experts in conversation about the most important advances in cardiovascular medicine in 2015. Presented in short interviews, this program is a must-see for all clinicians managing patients with, or at risk for, cardiovascular disease.
In this segment, Dr. Kausik Ray discusses where LDL-C targets may be going, the association between statins and new onset diabetes, and the introduction of new lipid-lowering drugs.
Participate in this eCME and stay informed!
This program is eligible for MOC RCPSC, Section 2 credits or you are eligible to claim up to 5 Mainpro+ certified credits by completing the CFPC’s Linking Learning to practice exercise.
You will receive your Certificate of Completion following participation in the interactive program elements located under the “Certificate” tab in the program player window. A link to the Linking Learning to Practice exercise on the CFPC website will be included in your certificate.
Potential for conflicts of interest:
Some speakers in this program have received payment/funding from the organizations supporting this program.
Speaker disclosures will be declared within the presentations.
Milan Gupta, MD, FRCPC, FACC
Associate Clinical Professor, Dep’t of Medicine
McMaster UniversityAssistant Professor, Department of Medicine,
University of Toronto, Medical Director
Canadian Cardiovascular Research Network
Narendra Singh, MD, FRCPC, FACC, FAHA
Director, Clinical Research
Atlanta Heart SpecialistsClinical Assistant Professor
Georgia Regents University
Kausik Ray, MBChB, MD, MPhil (Cantab), FRCP (Lon), FRCP (Ed), FESC, FACC, FAHA
School of Public Health
Imperial College London
|Statins and Diabetes
|Who Should Be Eligible for PCSK9 Inhibitors?